RSV vaccine effective for elderly

Recent studies have highlighted the effectiveness of RSV vaccines, particularly for vulnerable populations. A multi-state study published in The Lancet found that RSV vaccination provided approximately 80% protection against severe disease and hospitalization in adults aged 60 and older, with the highest risk observed in those aged 75 and above. Additionally, Pfizer's RSV vaccine Abrysvo demonstrated a 90% efficacy in preventing severe outcomes during its first vaccination season. The importance of vaccination is underscored by historical data showing significant hospitalizations and deaths due to RSV among older adults, with an estimated 60,000 to 160,000 hospitalizations annually prior to vaccine availability. Experts, including Dr. Shaun Grannis, emphasize the need for older adults to follow CDC guidance and get vaccinated as the respiratory disease season approaches. Both monoclonal antibody treatments and maternal vaccines are also available to protect neonates from severe RSV-related illnesses.